AbbVie, a drugmaker, has seen growth in its dividend and sales of immunosuppressants Skyrizi and Rinvoq over the past decade. An investment of $1,000 in AbbVie stock a decade ago would now be worth $3,350, or $4,105 if dividends were reinvested. The company is a solid dividend payer with a recent yield of 3.4%.

AbbVie, spun off from Abbott Laboratories in 2013, is a major global pharmaceutical company with a market value over $330 billion. While it lost patent protection for its blockbuster drug Humira, it has a promising drug pipeline. AbbVie’s average annual gain was 12.84%, outperforming the S&P 500 index.

The Motley Fool’s expert analysts have revealed the 10 best stocks to buy now, with AbbVie possibly making the list. Stock Advisor’s total average return is up 1,019%, beating the S&P by 841.12%. Potential for high returns on investments in the coming years with these recommended stocks. Join Stock Advisor for more top picks.

Read more at Yahoo Finance: If You’d Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here’s How Much You’d Have Today